z-logo
Premium
Intrapulmonary application of a 5‐lipoxygenase inhibitor using surfactant as a carrier reduces lung edema in a piglet model of airway lavage
Author(s) -
Ankermann Tobias,
Reisner Anja,
Wiemann Tina,
Koehler Heike,
Krams Matthias,
Krause Martin F.
Publication year - 2006
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.20392
Subject(s) - bronchoalveolar lavage , medicine , anesthesia , lung , respiratory distress , pulmonary compliance , pulmonary surfactant , edema , pulmonary edema , mechanical ventilation , leukotriene , asthma , chemistry , biochemistry
Leukotriene‐generated effects on microvascular integrity and polymorphonuclear leukocytes (PMNL) play a key role in the inflammatory process of the alveolar‐capillary unit in neonatal acute respiratory distress syndrome. We asked if intrapulmonary application of MK886, a 5‐lipoxygenase inhibitor, and the use of a porcine surfactant preparation (Curosurf™) as a carrier substance would improve lung function in a neonatal piglet model of airway lavage. Anesthetized, mechanically ventilated newborn piglets (n = 19) underwent repeated airway lavage to induce acute lung injury. Piglets then received either surfactant alone (S, n = 6), or MK886 admixed with surfactant (S + MK, n = 7), or an air‐bolus injection as control (C, n = 6). Measurements of gas exchange, lung function, extravascular lung water (EVLW), cell counts, and leukotriene B 4 (LTB 4 ) concentrations in bronchoalveolar lavage fluid (BAL) were performed during 6 hr of mechanical ventilation. Arterial oxygen partial pressure (PaO 2 ) (S, 13.8 ± 4.2 kPa, vs. S + MK, 20 ± 6.6; P  < 0.05), functional residual capacity (S, 15.1 ± 6.8 ml/kg, vs. S + MK, 18.8 ± 3.7 ml/kg; P  < 0.05), and EVLW (S, 29 ± 14 ml/kg, vs. S + MK 24 ± 4 ml/kg; P  < 0.05) were significantly improved in the MK886 group. This clinical effect was linked with a decrease in LTB 4 concentration in BAL (S, 3.5 (1.9–5.4) pg/ml, vs. S + MK, 1.6 (0.7–4.7) pg/ml; P  < 0.05) and an increase in IL‐8 (S, 2,103 (852–4,243) pg/ml, vs. S + MK, 3,815 (940–26,187) pg/ml; P  < 0.05). PMNL counts in BAL were reduced (S, 570 ± 42 cells/ml, vs. 275 ± 35 cells/ml; P  < 0.05). In conclusion, intrapulmonary application of the 5‐lipoxygenase inhibitor MK886 with surfactant as a carrier improves lung function by decreasing EVLW as the main response to LTB 4 reduction. Pediatr Pulmonol. 2006; 41:452–462. © 2006 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom